CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for JFL Life Sciences Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

JFL Life Sciences Ltd
309, Satyam Mall, Satellite Road
Phone: +91 7940036595p:+91 7940036595 AHMEDABAD, 380015  India Ticker: JFLLIFEJFLLIFE
Business Summary
JFL Life Sciences Limited is an India-based pharmaceutical company. The Company's business segment comprises the manufacturing and selling of pharmaceutical products. The Company is engaged in producing and marketing a wide range of formulations. The Company has manufacturing facilities with trading and related activities extending to the global market. Its manufacturing facilities are located at Kerala, Bavla, Ahmedabad, Gujarat. The Company's main product categories include dry powder injections, tablets and capsules (B-Lactam) solid oral dosage form, tablet and capsules (general), and ORS. Its beta lactam dry powder injection products include Ampicillin Injection, Cefotaxime Sodium Injection -250 Mg, Cefazoline Sodium Injection and meropenem injection - 1 gm. Its beta lactam tablet and capsule products include Cefadroxil Tablets 500 mg and Cefadroxil Capsules 500 mg. Its general tablet and capsule products include Azithromycin Tablets - 500 mg and Ofloxacin Tablets - 200 mg.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20213/31/2021-----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Managing Director Smiral A.Patel 42 1/18/2022 1/18/2022
Non-Executive Chairman of the Board Manishkumar J.Patel 40 2/10/2022 2/10/2022
Chief Financial Officer, Whole-Time Director Tejal S.Patel 41 6/1/2023 1/18/2022
3 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 10,998,441 (As of 3/31/2021)
Stock Exchange: NSE


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024